Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02707523 · ClinicalTrials.gov registry record · Phase 2
Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02707523 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 48 participants.
The verdict
NCT02707523, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled phase 2 trial will be conducted at a single tertiary pediatric intensive care unit (PICU). The study will include children with RSV infection who were admitted to the pediatric intensive care unit and require respiratory support via positive pressure ventilation (invasive and noninvasive).
Interventions
- DRUG Placebo
- DRUG Azithromycin 10 mg
- DRUG Azithromycin 20mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-01-01 |
| Est. Completion | 2020-06-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02707523
The ClinicalTrials.gov registry entry for NCT02707523 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02707523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02707523 about?
NCT02707523 is a clinical study titled "Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children". This randomized, double-blind, placebo-controlled phase 2 trial will be conducted at a single tertiary pediatric intensive care unit (PICU). The study will include children with RSV infection who were admitted to the pediatric intensive care unit and require respiratory support via positive pressure...
What is the current status of trial NCT02707523?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2016-01-01. Estimated completion is 2020-06-20.
What interventions are being tested in trial NCT02707523?
The interventions under investigation include: Placebo (DRUG), Azithromycin 10 mg (DRUG), Azithromycin 20mg (DRUG).
Who is sponsoring clinical trial NCT02707523?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.